2002
Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.
DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB, Stern DF. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Research 2002, 62: 6667-73. PMID: 12438265.Peer-Reviewed Original ResearchConceptsHER-2/neuCases of DCISDuctal carcinomaPrognostic indicatorNeu overexpressionHER-2/neu statusAdverse prognostic indicatorHormone receptor expressionPresence of calcificationIndicator of angiogenesisClinicopathological correlatesNeu levelsTumor sizeNeu expressionInvasive carcinomaHER-2Positivity rateReceptor expressionNeu statusBreast tumorigenesisDCISNeuCarcinomaMonoclonal antibodiesSignificant correlation
1996
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours
DiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.Peer-Reviewed Original ResearchConceptsHER-2/neuPrognostic indicatorBreast carcinomaInvasive breast carcinomaHER-2/ neuHuman breast tumorsFunctional assaysHuman breast carcinomaClinicopathological characteristicsPoor prognosisInvasive human breast tumoursLarge seriesBreast tumorsNeuMonoclonal antibodiesCarcinomaTumorsAntibodiesDifferent reportsOverexpressionReportAssaysPrognosis